newsfilter
← Latest News
Business Wire·

Sesen Bio Provides Strategic Update

Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizin